Submit a Request Contact Us

Ask Trio

The questions we have been asked, and what the record answered.

Every study below started as one question from one team. Each one shows the cohort, the documentation behind it, and the answer, with the note evidence that produced it.

  1. Relapsed / refractory myeloma · 23 July 2026

    Can you find our relapsed or refractory patients in the notes — and does cilta-cel's trial benefit hold up against a real-world control?

    Approximately 17,500 patients confirmed by reading their notes, and cilta-cel patients went 38.6 months before their next therapy against 9.4 for a matched comparator.

    • ~17,500 confirmed
    • 1,028-patient treated arm
    • vs CARTITUDE-4 and -1

    Read the Study

Your question isn't on this list yet.

Every study here started as one question from one team. Send us yours and we'll tell you what the record can support before anyone commits to a design.

Submit a Request